Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
obrindatamab · 1 trial · 1 indication
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.
Maximum Tolerated or Administrated Dose of obrindatamab and retifanlimab
| Arm | Type | Description |
|---|---|---|
| obrindatamab + retifanlimab | EXPERIMENTAL | B7-H3 x CD3 DART protein + anti-PD-1 antibody |
| Name | Type | Description |
|---|---|---|
| obrindatamab | BIOLOGICAL | B7-H3 x CD3 DART protein |
| retifanlimab | BIOLOGICAL | anti-PD-1 antibody |
Inclusion Criteria: * Histologically-proven, unresectable locally advanced or metastatic solid tumors of any histology that test positive for B7-H3 expression on tumor cells or vasculature for whom no approved therapy with demonstrated clinical benefit is available. For all tumor types, the require...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Obrindatamab is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a clinical trial setting to assess its safety and potential efficacy in patients with advanced solid tumors.
Obrindatamab is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX. The company is conducting clinical research to evaluate the drug's potential as a treatment for advanced solid tumors.
Obrindatamab is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in a completed Phase 1 trial to evaluate its safety and tolerability in patients with advanced solid tumors.
Obrindatamab has been studied in one clinical trial with the identifier NCT03406949, titled 'MGD009/MGA012 Combination in Relapsed/Refractory Cancer.' This Phase 1 trial, which has been completed, enrolled 25 participants with advanced solid tumors in the United States. The trial was uncontrolled and not randomized or double-blinded.
Obrindatamab is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in treating advanced solid tumors, though the exact mechanism of action remains unspecified in the public data.